SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid reports that the US president is considering reclassifying marijuana, which has sparked significant community discussion around potential benefits like tax relief and increased investment.  Traders are actively debating the likelihood and impact of the potential policy change, with some anticipating a major short squeeze while others express skepticism. Overall, the news has injected volatility and renewed interest in cannabis stocks.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending down despite positive earnings, as investors express concern regarding AI margin fears, customer concentration, and guidance. Community discussions revolve around whether the dip is an overreaction and a buying opportunity, or the start of a larger correction in the AI sector. Some traders speculate about potential for a dead cat bounce or further downside depending on market sentiment.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

Geo Group is trending as analysts updated their target price forecasts, sparking renewed community discussion. Community members are also discussing the company's potential to benefit from shifts in immigration policy and contract wins, while others debate the ethical implications of investing in private prisons. The stock's movement appears tied to broader political and policy cycles related to immigration and detention.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending amid speculation around potential cannabis rescheduling and executive action, driving optimism in the sector. The community is focused on potential catalysts like Trump's actions and Supreme Court decisions that could lead to significant re-rating and M&A activity. Discussions also center on identifying undervalued plays within the cannabis space, particularly those poised for substantial growth if regulatory changes materialize.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SUGP is trending as traders discuss its low float, potential short squeeze, and possible breakout, drawing comparisons to other HK stocks like $SMX and $OCG. Community members are closely watching for a golden cross setup and anticipate upward momentum if the stock moves above the $6 and $8 levels. The stock is known for crazy moves and potential for an after-hours run.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as investors debate its future, with some citing improving free cash flow and AI potential as reasons to buy, while others express concerns about leadership and profitability. Discussions also center around a potential buyout and the upcoming specs release. Sentiment appears mixed as the stock experiences volatility amid broader market fluctuations.

Argo Blockchain Plc operates as a blockchain technology company focused on large-scale mining of Bitcoin and other cryptocurrencies. It mines using purpose-built computers to solve cryptographic algorithms in the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company was founded in 2017 and is headquartered in London, the United Kingdom.

Argo Blockchain Plc - ADR

Argo Blockchain Plc

Argo Blockchain is trending due to discussions around its reverse stock split and London Stock Exchange delisting, with the community debating potential impacts. Some traders anticipate a rebound and short squeeze given the low float post-split, while others express skepticism about the company's financial health and potential for further dilution. Overall, the conversation reflects a mix of speculative hope and concern amidst restructuring efforts.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its position as the top meme coin on the Bitcoin network, emphasizing its unique attributes like a fair airdrop and fully open-source nature. Talk centers on its strong community, treasury growth, and potential listings, reinforcing bullish sentiment amidst market volatility. As a Bitcoin-native meme, it contrasts with other meme coins, emphasizing its permanence and cultural relevance within the crypto space.

RYTHM, Inc. engages in the development of hardware and software solutions for indoor agriculture. The company was founded on June 6, 2016 and is headquartered in Rolling Meadows, IL.

RYTHM Inc.

RYM is experiencing a surge in interest, with community members pointing to it as a potential runner and top gainer alongside other volatile stocks. Discussions revolve around potential after-hours pumps and comparisons to previous high-flying tickers, with some traders highlighting the stock's low float as a catalyst for significant price movement.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the Cannabis and Plant Propagation segments. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Aurora Cannabis is trending alongside other cannabis stocks amid speculation that the U.S. federal government might ease marijuana restrictions, with community members actively discussing the potential impacts of policy changes. Chatter revolves around an executive order from President Trump to reclassify cannabis, although some traders are wary of potential 'pump and dump' scenarios. Investors are weighing the implications for legacy cannabis companies like ACB given the broader sector's volatile history.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Afrezza revenue rose 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand.&nbsp;</li><li>Revenue from the V-Go insulin delivery patch, however, slipped 19% to $3.8 million due to low demand.&nbsp;</li><li>MannKind’s adjusted earnings per share came in at $0.07, above an analyst estimate of $0.02, according to data from Fiscal AI.&nbsp; &nbsp;</li></ul>Shares of MannKind Corporation (MNKD) rose 8% on Wednesday after the company reported 17% growth in total revenue to $82.13 million, thanks to significant growth in its Afrezza inhaled insulin sales.Afrezza revenue <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/05/3181424/29517/en/MannKind-Corporation-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html">rose</a> 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand, while royalties rose to $33.32 million. Revenue from the V-Go insulin delivery patch, however, slipped 19% to $3.8 million due to low demand.<h2 class="st-heading-2">Q3 Performance</h2>MannKind’s adjusted earnings per share came in at $0.07, up from $0.06 in the corresponding quarter of 2024, and above an analyst estimate of $0.02, according to data from Fiscal AI.The company ended the quarter with cash, cash equivalents, and investments of $286.3 million, after utilizing approximately $133.2 million and borrowing an additional $250 million to fund the <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-corporation-to-acquire-scpharmaceuticals/chssVp5Rd1m">acquisition</a> of scPharmaceuticals, which was completed in October.The acquisition is expected to accelerate MannKind’s revenue growth with the addition of Furoscix to its portfolio. Furoscix is used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD).“The acquisition of scPharmaceuticals marks a significant expansion of our commercial capabilities and is expected to accelerate growth of our product revenues and build upon our commitment to delivering innovative, patient-centric therapies,” said Michael Castagna, CEO of MannKind.The company has now submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged four to 17 years. The agency is expected to make a decision on the application by May 29, 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD stock</a> fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/61;" src="data:image/png;base64,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" width="624" height="61" alt="MNKD's Sentiment Meter and Message Volume as of 11:00 a.m. ET on Nov. 5, 2025 | Source: Stocktwits"><figcaption>MNKD's Sentiment Meter and Message Volume as of 11:00 a.m. ET on Nov. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Wednesday’s gain in stock price might not last.<stembedurl>https://stocktwits.com/nomalarkey/message/635009498</stembedurl>Another sounded optimistic about the stock’s prospects.<stembedurl>https://stocktwits.com/6Figs/message/635008031</stembedurl>MNKD stock is down 8% this year and approximately 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-executives-including-cfo-rally-for-musk-s-one-trillion-pay-package/cL2qZJZREGA">Tesla Executives Including CFO Rally For Musk’s $1T Pay Package</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mannkind Corp and the company's inhalable insulin product. Company employee demonstrating how the device is used. (Photo by Lawrence K. Ho/Los Angeles Times via Getty Images)

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters

The company has now also submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged 4-17 years.

Equity

The company has now also submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged 4-17 years.


<ul class="summary-bullets"><li>In Q3, Ibsrela saw highest demand since launch and recorded revenue of $78.2 million, marking a growth of 92%.</li><li>Ardelyx’s net loss in the quarter, however, was $1 million, compared to net loss of $0.8 million reported in the corresponding quarter of 2024.</li><li>The company is now looking forward to filing an investigational new drug submission to the FDA for its early-stage candidate RDX10531 in 2026.&nbsp; &nbsp;</li></ul>Ardelyx shares soared 22% in Friday’s premarket session after the company raised guidance for its irritable bowel syndrome drug Ibsrela, which saw the highest demand in the third quarter (Q3).“IBSRELA continues to outperform and is the foundation of our portfolio and the main engine for Ardelyx's future growth,” CEO Mike Raab said on the company’s earnings call on Thursday.“Demand growth is broad-based and demonstrates how vital this therapy is for patients. We expect this momentum to continue through Q4 and beyond, and as a result, we are raising our guidance,” he added.<h2 class="st-heading-2">Revised Guidance, Q3 Fineprint</h2>The company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-third-quarter-2025-financial-results-and">expects </a>revenue to be between $270 million and $ 275 million from Ibsrela for the full year. In the third quarter, the drug generated revenue of $78.2 million, marking a growth of 92%, and accounting for 74% of the company’s total product revenue for the period.U.S. revenue for Xphozah, used to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, was $27.4 million in Q3 despite dynamic market situations, the company said. Ardelyx now expects continued growth in the fourth quarter for the drug.Total revenue in the quarter, including product and licensing revenue, came in at $110.3 million, above an analyst estimate of $100.54 million. Net loss in the quarter was $1 million, slightly wider than the $0.8 million net loss reported in the corresponding quarter of 2024.<h2 class="st-heading-2">Future Pipeline</h2>In the third quarter, Ardelyx began developing RDX10531, an early-stage drug candidate. The company is now looking forward to filing an Investigational New Drug submission with the U.S. Food and Drug Administration for the candidate in 2026, to initiate trials in humans.“We are committed to building a broad, sustainable pipeline, capitalizing first on an internal asset while, in parallel, we explore external opportunities,” Raab said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/57;" src="data:image/png;base64,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" width="623" height="57" alt="ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits"><figcaption>ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the stock hitting a per-share price of $7 today.<stembedurl>https://stocktwits.com/badgermobile/message/634454149</stembedurl>Another expressed optimism about the CEO saying on the earnings call that it is open to external business opportunities.<stembedurl>https://stocktwits.com/Dragan7/message/634447443</stembedurl>ARDX stock is down 1% year-to-date and by approximately 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shareholder-gavin-baker-supports-elon-musk-1-trillion-pay-plan/cLGqGXNR3Ul">Atreides’ Gavin Baker Backs Elon Musk’s $1T Tesla Pay Deal Despite Broad Opposition</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela

The company now expects revenue from Ibsrela to be between $270 million and $275 million for the full year.

<ul class="summary-bullets"><li>The company announced the exercise of existing warrants held by an institutional investor.</li><li>The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.&nbsp;</li><li>The transaction is expected to close on or about October 28, the company said.&nbsp; &nbsp;</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 6% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.The warrants were previously issued in March and August 2024, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-31-Million-in-Gross-Proceeds/default.aspx">said</a>. The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.The new warrants will be exercisable immediately and will expire five years from the date of issuance, the company said.The closing of the translation is expected to occur on or about October 28, it added.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/SLS"> SLS stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user recommended holding the stock, opining that it will now go higher.<stembedurl>https://stocktwits.com/Kevoo/message/633843705</stembedurl>Another dismissed concerns of dilution, terming the warrant exercise a “not that big deal.”<stembedurl>https://stocktwits.com/Risulom/message/633841655</stembedurl> In September, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-in-spotlight-after-institutional-investor-exercises-existing-warrants/chwNYhvRdvv">announced</a> that an institutional investor had exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025, the company then said.SLS stock is up by 80% this year and by about 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7">Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is SELLAS Life Sciences Stock Falling Today?

Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 5% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.

Why Is SELLAS Life Sciences (SLS) Stock Falling Today?

<ul class="summary-bullets"><li>Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z.</li><li>The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial.</li><li>The patient is being closely monitored and receiving medical intervention, the company said. &nbsp;</li></ul>Intellia Therapeutics, Inc. (NTLA) on Monday said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z after a patient was hospitalized.The company has paused dosing in a trial that enrolled patients with transthyretin amyloidosis with cardiomyopathy and another that enrolled patients with polyneuropathy. Transthyretin amyloidosis with cardiomyopathy is a severe and progressive heart failure caused by the buildup of misfolded amyloid fibrils, derived from the transthyretin protein, in the heart muscle. Transthyretin amyloidosis with polyneuropathy, meanwhile, is a progressive, multisystem disease caused by the buildup of abnormal proteins in the body's organs and tissues.&nbsp;<h2 class="st-heading-2">Why The Pause?</h2>The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial, raising concerns of drug-induced liver injury. The patient was dosed with Nex-z on September 30.The hospitalized patient is being closely monitored and receiving medical intervention, the company said.<h2 class="st-heading-2">What Are The Company’s Plans?</h2>Meanwhile, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174462/0/en/Intellia-Therapeutics-Provides-Update-on-MAGNITUDE-Clinical-Trials-of-Nexiguran-Ziclumeran-nex-z.html">said</a> it is consulting with experts, considering potential risk mitigation strategies, and engaging with regulatory authorities.<blockquote>“In line with our commitment to patient safety, we have taken immediate action to temporarily pause enrollment in MAGNITUDE and MAGNITUDE-2 as we investigate this recent event. As we focus on ensuring the health of this patient, we also are engaging with regulatory authorities and other stakeholders globally to develop a strategy to resume enrollment as soon as appropriate.”&nbsp; – John Leonard, CEO, Intellia Therapeutics</blockquote>Nex-z or Nexiguran Ziclumeran is a therapy based on gene editing technology. It is designed to inactivate the TTR gene that encodes the transthyretin protein. As of Monday, more than 700 patients have been enrolled in the two trials in which Intellia has paused dosing, and over 450 have already been dosed with Nex-z.Shares of the company slumped 43% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> soared from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.NTLA stock has more than doubled this year and gained about 57% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

Why Did NTLA Stock Tumble 43% Pre-Market Today?

Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z.

<ul class="summary-bullets"><li>The payment was in connection with the dosing of the first patient in a late-stage registrational trial of Ziftomenib.</li><li>Kura Oncology and Kyowa Kirin had entered into a deal in November 2024 to jointly develop and commercialize Ziftomenib. &nbsp;</li></ul>Kura Oncology (KURA) said on Friday that it received a $30 million milestone payment under its collaboration agreement with Japan-based Kyowa Kirin, inked late last year.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/24/3172720/35186/en/Kura-Oncology-Receives-30-Million-Development-Milestone-Payment-in-Ziftomenib-AML-Program-with-Kyowa-Kirin.html">payment</a> was in connection with the dosing of the first patient in a late-stage registrational program of Ziftomenib evaluating the drug in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed acute myeloid leukemia with certain conditions. The companies announced the launch of the said trial on September 29.The program includes two late-stage trials intended to support potential U.S. accelerated approval and full approval. The trial is expected to enroll patients at up to 200 sites worldwide.According to Kura, the late-stage program is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings.<h2 class="st-heading-2">Terms Of The Deal</h2>Kura Oncology and Kyowa Kirin had entered into a deal in November 2024 to jointly develop and commercialize Ziftomenib. Under the agreement, Kura is eligible to receive up to $1.2 billion in total milestone payments, including near-term milestone payments. &nbsp;As per the terms of the agreement, Kura will lead development, regulatory, and commercial strategy in the U.S. while Kyowa leads it outside the U.S.<a href="https://stocktwits.com/symbol/KURA">KURA shares</a> traded 6% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around KURA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.KURA stock is up by over 4% this year but down by about 49% over the past 12 months.Read also:<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/jp-morgan-to-let-clients-use-bitcoin-ethereum-as-loan-collateral-by-year-end/cLGJVtKR3sH"> JPMorgan To Let Clients Use Bitcoin, Ethereum As Loan Collateral By Year-End: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement

The payment was in connection with the dosing of the first patient in a late-stage registrational trial of Ziftomenib.

Protalix BioTherapeutics (PLX) and Chiesi Global Rare Diseases announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the request to approve a new dosing regimen for Elfabrio.The company was seeking approval of a dosing regimen of 2 mg/kg body weight infused every four weeks for Elfabrio. The currently approved dosing regimen in the European Union is 1 mg/kg body weight infused every two weeks for the treatment of adults with confirmed Fabry disease, a rare genetic disorder leading to the buildup of a fatty substance called globotriaosylceramide in cells throughout the body.Fabry disease can cause a range of serious signs and symptoms, including fatigue, chronic pain, gastrointestinal issues, decreased ability to sweat, progressive kidney failure, heart complications, and increased risk of stroke. It affects both males and females and is caused by a deficiency of the enzyme alpha-galactosidase A.However, Protalix CEO <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/17/3168523/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-Biotherapeutics-Acknowledge-CHMP-Negative-Opinion-on-Every-Four-Week-Dosing-Regimen-of-Elfabrio-pegunigalsidase-alfa-in-the-EU.html">said</a> that the results of the review do not change the priority of the company to reduce treatment burden for patients with Fabry disease. The two companies also clarified that they intend to keep working together.Shares of PLX dropped 28% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PLX">PLX stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.Protalix submitted the data to the committee for review, which included two new studies and analyses from prior studies. However, the data was not deemed sufficient to conclude on efficacy, the company saidPLX stock is up by 28% this year and by 120% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/boston-scientific-to-acquire-privately-held-pain-solutions-developer-nalu-medical-for-about-533-million/ch6se8ER38d">Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors?

However, Protalix CEO said that the results of the review do not change the priority of the company to reduce treatment burden for patients with Fabry disease.

Shares of TrueCar (TRUE) rallied 60% on Wednesday morning after the company said that it has entered into a definitive agreement under which Fair Holdings, Inc., an entity led by TrueCar founder Scott Painter, will acquire the company in an all-cash, go-private transaction at $2.55 per share.This represents a premium of about 72% from the stock’s closing price on Tuesday and amounts to an equity value of approximately $227 million based on current basic shares outstanding.TrueCar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/truecar-to-be-acquired-by-founder-led-strategic-and-financial-investor-group-in-all-cash-go-private-transaction-302584766.html">said</a> that Fair Holdings is negotiating with various financial and strategic investors to syndicate the financing of the deal with equity investments.TrueCar Chair Barbara Carbone said that the board unanimously approved the transaction after a thorough and careful evaluation. “...we are confident it is in the best interest of TrueCar stockholders and other stakeholders,” they added.Upon completion of the deal, Scott Painter will be the CEO of the company again, it said. The transaction is expected to close in the fourth quarter of 2025 or early 2026, subject to the receipt of certain approvals. Once the deal is completed, TrueCar will no longer trade on the bourse.However, if Fair Holdings is unable to complete the transaction, it has agreed to pay a reverse termination fee to TrueCar, the company said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TRUE">TRUE stock</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:586/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_1_43_05_PM_png_7f46c96902.webp" alt="TRUE's Sentiment Meter and Message Volume as of 1:43 p.m. ET on Oct. 15, 2025 | Source: Stocktwits" width="586" height="63"><figcaption>TRUE's Sentiment Meter and Message Volume as of 1:43 p.m. ET on Oct. 15, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits applauded the buyout as a “good deal.”<stembedurl>https://stocktwits.com/mickymatthews/message/632395006</stembedurl>Another, however, opined that the price is low.<stembedurl>https://stocktwits.com/mickymatthews/message/632389499</stembedurl>TRUE stock is down by 36% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rigetti-computing-stock-slides-8-after-hitting-record-highs-on-tuesday/ch6F2raR3VG">Rigetti Computing Stock Slides 8% After Hitting Record Highs On Tuesday — Traders Warn Of More Downside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Employees of TrueCar celebrate while ringing the opening bell for the Nasdaq Exchange in Times Square on May 16, 2014 in New York City. TrueCar was having it's initial public offering (IPO) on the Nasdaq exchange. (Photo by Andrew Burton/Getty Images)

TrueCar Shares Soar Following $227M Go-Private Deal

The per share purchase price represents an equity value of $227 million and a premium of about 72% from the stock’s closing price on Tuesday. 

Candel Therapeutics (CADL) on Tuesday said that it has entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN).The loan facility <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166168/0/en/Candel-Therapeutics-Enters-into-130-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html">comprises</a> four tranches. While the first tranche of $50 million will be drawn upon closing of the agreement, the second and third tranche totaling $50 million will be available to draw on the achievement of certain milestones, and the fourth tranche of $30 million will be available at the lender’s discretion, the company said. The loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.Proceeds from the loan will be used to refinance certain loan and security agreements, as working capital, and to fund general corporate purposes. The company also said it intends to use the proceeds towards the initiation of a pivotal phase 3 clinical trial of its lead candidate CAN-2409 in non-small cell lung cancer in the second quarter of 2026.Candel Therapeutics shares traded 7% lower on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CADL">CADL stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Candel CFO Charles Schoch said that the strategic financing, in addition to the company’s cash and cash equivalents of $87.2 million as of September 30, strengthens the company’s balance sheet and is also expected to support the company through CAN-2409’s potential launch in early localized prostate cancer and into commercialization.The company plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of CAN-2409 for prostate cancer in the fourth quarter of 2026.CADL stock is down by 31% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer 

The company said that the loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.

Esperion (ESPR) on Friday said that it has entered into a settlement agreement with Dr. Reddy’s Laboratories and its affiliate under which the latter has agreed not to market a generic version of either Nexletol or Nexlizet in the United States before April 19, 2040.The agreement <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/03/3160929/0/en/Esperion-Reaches-Settlement-Agreement-with-ANDA-Filer-Dr-Reddy-s-Laboratories-Not-to-Market-Generic-Versions-of-NEXLETOL-bempedoic-acid-and-NEXLIZET-bempedoic-acid-and-ezetimibe-Pr.html">resolves</a> the patent litigation brought by Esperion against Dr. Reddy’s Laboratories after it submitted an Abbreviated New Drug Application seeking approval to market a generic version of each of Nexletol and Nexlizet.The two drugs are used to reduce low-density lipoprotein (LDL) or "bad" cholesterol in adults with high blood cholesterol levels, known as primary hyperlipidemia. Shares of Esperion traded 8% higher in the pre-market session at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ESPR">ESPR stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.Esperion reached a settlement agreement with Micro Labs USA and its affiliate; Hetero USA, and its affiliates; and Accord Healthcare earlier this year with respect to their generic versions of Nexletol.The bempedoic acid portion of the two drugs is claimed in an Esperion patent scheduled to expire in December 2030, the company said. With the settlement with Dr. Reddy’s, there are no remaining challenges regarding the validity or infringement of the said patent in the pending patent litigation, it added.The company also stated that there is no assurance that the ongoing patent litigation against the remaining defendants, including Alkem Laboratories, will allow a generic version of the cholesterol drugs to be marketed in the U.S. before April 19, 2040.ESPR stock is up by 32% this year and by approximately 48% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ovid-therapeutics-stock-rally-pre-market-after-positive-results-from-trial-of-potential-seizure-treatment/chCuj8HR3Q2">Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs

The company said that Dr. Reddy’s Laboratories has agreed not to market a generic version of either Nexletol or Nexlizet in the U.S. before April 19, 2040. 

Larimar Therapeutics, Inc. (LRMR) on Monday announced positive data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich’s Ataxia.Friedreich's Ataxia (FA) is a rare, inherited disorder causing progressive damage to the nervous system, leading to symptoms like poor coordination, difficulty walking, and sensory loss, as well as heart disease and scoliosis. It is caused by a mutation in the FXN gene, resulting in a deficiency of the mitochondrial protein frataxin.In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157570/0/en/Larimar-Therapeutics-Announces-Positive-Data-from-Ongoing-Long-term-Open-Label-Study-and-Updates-to-Nomlabofusp-Program-for-Friedreich-s-Ataxia.html">study,</a> an increase in skin frataxin (FXN) levels was observed with short- and long-term daily Nomlabofusp. All ten participants with data at six months achieved skin FXN levels over 50% of median levels in healthy volunteers, the company stated. It added that consistent directional improvement across multiple clinical outcomes was also observed after a year of Nomlabofusp treatment.“These new data, as well as the improvement in abnormal lipid profiles observed in prior completed studies, provide support that nomlabofusp increases FXN in patients with FA and that the strategy of FXN replacement has the potential to result in a clinical benefit,” said CEO Carole Ben-Maimon.Shares of the company tumbled 47% in the pre-market session after the company reported that anaphylaxis, or a severe allergic reaction, was observed in seven participants in the open-label study, and they were subsequently withdrawn from the study. Most instances of anaphylaxis occurred on the initial day of administration and most within the first six weeks of dosing, it noted.Other discontinuations in the study included three cases of generalized urticaria, one seizure, one vasovagal event, and two non-treatment-related discontinuations, it said.The company said that it consulted experts and decided to modify its starting dose regimen after the two most recent cases of anaphylaxis. The U.S. Food and Drug Administration has agreed with the approach, the company said. Larimar is looking to submit an application for approval of Nomlabofusp to the FDA in the second quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.LRMR stock is down by 2% this year and by 42% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study

The company said that anaphylaxis or a severe allergic reaction was reported in seven participants in the open-label study evaluating Nomlabofusp in participants with Friedreich’s ataxia. 

Current Price	$58.19
Prev Close	$61.15
Open	$61.22
Dividend Yield	N/A
50-Day Moving Average	$53.53
Beta	N/A
Avg. Volume	1.52M
PE Ratio	N/A

52-Week High	$61.26
52-Week Low	$21.15
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

URTY
ProShares UltraPro Russell2000

Feed

News

Sentiment

Fundamentals

Info

Latest URTY News

URTYProShares UltraPro Russell2000